US 12,698,232

Application 17/831,874 · Granted Aug 4, 2026

Foldable cover article with reduced hazardous projections

Estimated expiration

September 28, 2040

13y 314d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTCN2019122786: Resource not found (404)
Earliest effective filing
Dec 3, 2019
+ 20 years
Dec 3, 2039
PTA +300d
Sep 28, 2040
No TD
—
Final
Sep 28, 2040

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
June 3, 2022
Earliest effective filing
December 3, 2019
Issue date
August 4, 2026
PTA
+300 days
Base expiry (before PTA)
December 3, 2039

December 3, 2019 + 20 years = December 3, 2039 + 300 PTA days = September 28, 2040

  • Continuation of application PCTCN2019122786, filed Dec 3, 2019

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/831,874 · US 12,698,232

PatentReply compiles the prosecution history behind US 12,698,232: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12698232

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.